US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by a US government agency.
US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and
